In Brief: Schering-Plough's Nasonex
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's Nasonex: NDA filed Sept. 30 for the prescription mometasone furoate aqueous nasal spray. Schering is seeking use of the once-daily Nasonex for "prophylaxis and treatment of symptoms of seasonal allergic rhinitis and the treatment of perennial rhinitis in adults and adolescents 12 years of age and older," the company reports. Mometasone furoate also is being developed in dry powder and metered-dose inhaler formulations for bronchial asthma...